Navigation Links
BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl

ections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, the application of funds, or the timing for completion and results of scheduled or additional clinical trials and FDA review of the Company's formulations and products, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all.

Contact

Investor Relations Group
Investor Relations:
James Carbonara, 212-825-3210
or
Media Relations:
Bill Douglass, 212-825-3210


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/1/2008)...ORE, Dec. 1 S*BIO Pte Ltd today an...al of SB1518, a potent and orally-active JAK2 inhi... patients with chronic idiopathic myelofibrosis (C...e the safety and tolerability of SB1518 in patient...ents. The Phase 1 part of the study will assess t...
(Date:12/1/2008)...TH MEETING, Pa., Dec. 1 ...nced that dosing of subjects has begun in study MS...se Phase 1b study of trodusquemine (MSI-1436) in o...a novel therapeutic for the treatment of type 2 di...herally to regulate insulin and leptin pathways th...
(Date:11/30/2008)... , CHICAGO, Dec. 1 O...cerebral blood flow and a greater number of small ...presented today at the annual meeting of the Radio... The study, conducted at the University of Nort... compare brain scans of older adults who exercise ...
(Date:11/26/2008)...TER, Minn., Nov. 26 Chi...are at significantly increased risk of developing ...ndings of a Mayo Clinic study published this mont...ican Academy of Pediatrics. , , The retrosp...atients with strabismus (misaligned eyes) and comp...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Eye Divergence in Children Triples Risk of Mental Illness 2Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 1Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 2Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 3Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 4Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 5Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 6Tumor suppressor genes speed up and slow down aging in engineered mouse 20708 1Nations Only Health Museum Makes You Sole Focus of New Exhibit Gallery 20705 1Nations Only Health Museum Makes You Sole Focus of New Exhibit Gallery 20705 2Nations Only Health Museum Makes You Sole Focus of New Exhibit Gallery 20705 3Bio Pharma Industry Experts Deliver M 26A Value Through Integration Excellence 5711 1Bio Pharma Industry Experts Deliver M 26A Value Through Integration Excellence 5711 2
...P-1 in Neuropathic Pain, TARRYTOWN, N.Y., May 03, ... announced today that it will present new data for...26th Annual,Scientific Meeting of the American Pai...ented topical cream formulation of two,FDA-approve... a,product candidate intended for use in the manag...
...nal Conference on Antiviral,Research, SAN DIEGO, M...rmaceuticals, Inc. , a biopharmaceutical research ... proprietary product,candidates for the treatment ... that it presented results demonstrating synergist...d flu) viruses when,the Company,s broad-spectrum a...
Other Medicine Technology:EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 2EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 3EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 4EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 5ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 2ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 3
(Date:12/2/2008)... NDA with FDA in Early to Mid-2009 , , WARR...velopers of PharmFilm(R) technology and a drug del... pharmaceutical products, and Strativa Pharmaceuti...rmaceutical Companies, Inc. (NYSE: PRX ), today ... bioequivalence studies for a thin film formulatio...
(Date:12/2/2008)...c. 2 With the bright lights, sweet...holidays may be an exciting time of year for any c..., especially with today,s tough economy. Whether ...ptying their wallets, or spending hours traveling ...elax, and even less time to be alone and romantic ...
(Date:12/2/2008)...Dec. 2 Aduromed Industri...ovider of medical waste treatment,systems, today ... on November,24, 2008 to protect the Company,s pr...nerized MedClean Systems that provide a turnkey so...zation and volume reduction. , The patent a...
(Date:12/2/2008).... 2 Mylan Inc. (NYSE: ... Mylan Pharmaceuticals Inc., have entered,into a ... Corp., Novartis,Corp. and Novartis International...sion of Novartis, Femara(R). , Mylan,s Vice...re very,pleased to have reached this agreement, w...
Breaking Medicine News(10 mins):Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
... the risk of diabetes in the Indigenous population...ott, Pro-vice Chancellor of the Division of Health...ows that while clinical care of adults with diabet...ndigenous Australians are developing the disease. ...
... epidemic of diabetes in the US is out. Spending o.... According to a drug trend report released by th...ailed only cholesterol medications in total prescr...n 2006. An aging population and the alarming rise...
...disfiguring accident that nearly killed him, but h...s home on Andrews Air Force Base in Maryland. N...e, that is, because of his brand-new nose. In a s... over a year-long period that ended with removal o...
...al Boston) and colleagues have identified the canc... soft-tissue sarcoma of childhood. 'Identifying ...ved genetic programs underlying self-renewal in ER... into how to destroy these cell types in establish...
Other Medicine News:Health News:Spending on Diabetes Drugs Soars in US 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 3Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 4Health News:Pediatric Cancer Stem Cell Identified 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: